Clinical Analysis Of Treatment For 53 Patients With Metastatic Breast Cancer

Objective: To give a summary of the treatment of metastatic breast cancer (MBC) patients in our department in recent 4 years, give a comparison of the efficacy and toxicity of different chemotherapy regimen, evaluate the status of gemcitabine and cyclophosphamide chemotherapy regime in MBC patients, and evaluate the role of endocrine and molecular targeted therapy.Methods: 53 MBC patients in the first of Jilin university from Jan 2007 to Dec 2010 were treated with gemcitabine plus cyclophosphamide(GC), including anthracycline and taxane (including AT), taxane plus capecitabine (TX) and other regimens, other major treatment include endocrine therapy, molecular targeted therapy. We analysis the difference of toxicity and recent efficacy of different groups, and compare the factors that may affect the recent efficacy, and evaluate the effect of endocrine therapy and molecular targeted therapy in the treatment of MBC.Results: The outcomes include: complete remission(n=2, 2%), partial remission(n=49, 50%), stability(n=38, 38.3%), and disease progression(n=9, 9.2%), the objective response rate was 52.0%,GC is lower than including AT regime. The median time to progression was 8 months, the difference between these four groups was not significant difference. The number of metastatic sites and distant metastasis is the factors of recent therapy effect. Chemohormonal therapy can improve TTP significantly. The main toxicity was myelosuppression and gastrointestinal reactions, including AT group is higher than GC group,TX group is higher than GC group in the incidence rate of hand-foot syndrome. The adverse reactions of endocrine therapy and molecular targeted therapy are mild. Conclusion : Breast cancer is chemotherapy-sensitive tumor, most patients can ease after chemotherapy; Including AT regimen should be the first choice for anthracycline and taxane-sensitive patients; GC is a safe and effective regimen for MBC; The number of metastatic sites and distant metastasis is the factors of recent therapy effect; Endocrine therapy can improve TTP significantly; Herceptin has significant effect for HER-2 positive patients.